


# GSK delivers strong Q3 sales of £9.1 billion, +5% AER, +10% CER



Pharma  
**£4.4bn**  
+ 10%

Vaccines  
**£2.2bn**  
+ 13%

Consumer  
**£2.5bn**  
+ 8%



All % at constant exchange rates (CER)

Total Group operating margin

**21.4%**

Adjusted Group operating margin

**31.7%**

Total EPS

**23.3p**  
+ 3%

Adjusted EPS

**36.6p**  
+ 10%

Free cash flow


**£1.2bn**

Dividend

**19p**

Emma Walmsley, Chief Executive Officer, GSK said:

“GSK has delivered another quarter of strong business performance, with double-digit sales growth in Pharmaceuticals and Vaccines, increased momentum in Consumer Healthcare, and continued discipline on costs. This has allowed us to improve our full year guidance and, alongside the progress in strengthening our R&D pipeline, reinforces our confidence in the outlook for a step change in growth and performance in 2022 and beyond. We also continue to make excellent progress toward unlocking the value of Consumer Healthcare through a successful demerger in mid-2022.”



Engineered t-cell attacking cancer tumour

Journalists/media see press release on [www.gsk.com](http://www.gsk.com) for full details on Q3 2021.

Please read the cautionary statement regarding **forward-looking statements** and the definitions and reconciliations for non-IFRS measures on pages 60 to 61 of the press release.